The demand for rapid diagnostic analysis is putting pressure on companies to move testing out of central laboratories and into the point-of-care environment. According to Markets and Markets Inc.’s latest report, “This market (microfluidics) is mainly driven by the rising demand for point-of-care (POC) testing, increasing demand for microfluidic chip miniaturization as it offers lower testing time and improved portability, growing Asian market, rising incidences of lifestyle diseases, increasing R&D expenditure and healthcare spending, and growing stem cell and cancer research…In 2014, the in-vitro diagnostics application segment accounted for the largest share of the global microfluidics market.”
When testing is closer to the patient, turnaround time, sample touch time and logistics are all reduced. Rapid results improve patient care and outcomes, and reduce required blood and healthcare resources.
Hence, why has it taken so long for POC to be realized?